Interstitial pneumonitis in acute leukemia patients submitted to T-depleted matched and mismatched bone marrow transplantation

被引:13
作者
Aristei, C
Aversa, F
Chionne, F
Martelli, MF
Latini, P
机构
[1] Gen Hosp, Inst Radiotherapy Oncol, Perugia, Italy
[2] Gen Hosp, Dept Haematol, Perugia, Italy
[3] Gen Hosp, Bone Marrow Transplantat Unit, Perugia, Italy
[4] Gen Hosp, Dept Med Phys, Perugia, Italy
[5] Univ Perugia, I-06100 Perugia, Italy
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1998年 / 41卷 / 03期
关键词
interstitial pneumonitis; T-depleted BMT; matched BMT; mismatched BMT; acute leukemia;
D O I
10.1016/S0360-3016(98)00068-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To identify factors that could contribute to interstitial pneumonitis (IP), which remains one of the major causes of morbidity and mortality after both matched and mismatched bone marrow transplantation (BMT). Methods and Patients: Ninety acute leukemia patients received an allogeneic T-depleted matched (n = 54) or mismatched (N = 36) BMT. They were preconditioned with total body irradiation (TBI), thiotepa, rabbit anti-thymocyte globulin, and cyclophosphamide. The TBI scheme was hyperfractionated in matched, and a single dose in mismatched patients. The dose to the lungs was reduced in both groups. Results: Five of the 54 matched patients developed IF. All cases mere fatal. There were 16 cases of TP, 13 fatal, in the mismatched group. The probability of developing IP was 11.3 +/- 4.9% and 48.6 +/- 9.0%, respectively. The between-group difference was statistically significant (p < 0.0001). The type of transplant and the TBI scheme were the most important parameters for IP development in univariate analysis, whereas acute graft-versus-host disease, disease stage and sex were nonsignificant. Median follow-up was 342 days (range 17-2900). Conclusions: The low incidence of IP in matched patients and the lack of idiopathic cases are evidence for the validity of the TBI schedule. In contrast, the incidence in mismatched patients remains too high; therefore, new strategies should be studied in an attempt to lower it. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:651 / 657
页数:7
相关论文
共 50 条
[1]   Natural killer (NK)-cell function and antileukemic activity of a large population of CD3(+)/CD8(+) T cells expressing NK receptors for major histocompatibility complex class I after ''three-loci'' HLA-incompatible bone marrow transplantation [J].
Albi, N ;
Ruggeri, L ;
Aversa, F ;
Merigiola, C ;
Tosti, A ;
Tognellini, R ;
Grossi, CE ;
Martelli, MF ;
Velardi, A .
BLOOD, 1996, 87 (09) :3993-4000
[2]   EFFECT OF HLA COMPATIBILITY ON ENGRAFTMENT OF BONE-MARROW TRANSPLANTS IN PATIENTS WITH LEUKEMIA OR LYMPHOMA [J].
ANASETTI, C ;
AMOS, D ;
BEATTY, PG ;
APPELBAUM, FR ;
BENSINGER, W ;
BUCKNER, CD ;
CLIFT, R ;
DONEY, K ;
MARTIN, PJ ;
MICKELSON, E ;
NISPEROS, B ;
OQUIGLEY, J ;
RAMBERG, R ;
SANDERS, JE ;
STEWART, P ;
STORB, R ;
SULLIVAN, KM ;
WITHERSPOON, RP ;
THOMAS, ED ;
HANSEN, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (04) :197-204
[3]  
Aristei C, 1996, Cancer J Sci Am, V2, P330
[4]  
ARISTEI C, 1996, INT J RAD ONCOL B S1, V36
[5]   SUCCESSFUL ENGRAFTMENT OF T-CELL-DEPLETED HAPLOIDENTICAL 3-LOCI INCOMPATIBLE TRANSPLANTS IN LEUKEMIA PATIENTS BY ADDITION OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR-MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS TO BONE-MARROW INOCULUM [J].
AVERSA, F ;
TABILIO, A ;
TERENZI, A ;
VELARDI, A ;
FALZETTI, F ;
GIANNONI, C ;
IACUCCI, R ;
ZEI, T ;
MARTELLI, MP ;
GAMBELUNGHE, C ;
ROSSETTI, M ;
CAPUTO, P ;
LATINI, P ;
ARISTEI, C ;
RAYMONDI, C ;
REISNER, Y ;
MARTELLI, MF .
BLOOD, 1994, 84 (11) :3948-3955
[6]   INTERSTITIAL PNEUMONITIS FOLLOWING BONE-MARROW TRANSPLANTATION AFTER LOW-DOSE RATE TOTAL-BODY IRRADIATION [J].
BARRETT, A ;
DEPLEDGE, MH ;
POWLES, RL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1983, 9 (07) :1029-1033
[7]   MARROW TRANSPLANTATION FROM RELATED DONORS OTHER THAN HLA-IDENTICAL SIBLINGS [J].
BEATTY, PG ;
CLIFT, RA ;
MICKELSON, EM ;
NISPEROS, BB ;
FLOURNOY, N ;
MARTIN, PJ ;
SANDERS, JE ;
STEWART, P ;
BUCKNER, CD ;
STORB, R ;
THOMAS, ED ;
HANSEN, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (13) :765-771
[8]  
Bishop MR, 1996, BONE MARROW TRANSPL, V18, P747
[9]   ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC-LEUKEMIA DURING 1ST COMPLETE REMISSION [J].
BLUME, KG ;
FORMAN, SJ ;
SNYDER, DS ;
NADEMANEE, AP ;
ODONNELL, MR ;
FAHEY, JL ;
KRANCE, RA ;
SNIECINSKI, IJ ;
STOCK, AD ;
FINDLEY, DO ;
LIPSETT, JA ;
SCHMIDT, GM ;
NATHWANI, MB ;
HILL, LR ;
METTER, GE .
TRANSPLANTATION, 1987, 43 (03) :389-392
[10]   MARROW TRANSPLANTATION FROM HLA NON-IDENTICAL FAMILY DONORS FOR THE TREATMENT OF LEUKEMIA - A PILOT-STUDY OF 15 PATIENTS USING ADDITIONAL IMMUNOSUPPRESSION AND T-CELL DEPLETION [J].
CAHN, JY ;
HERVE, P ;
FLESCH, M ;
PLOUVIER, E ;
RACADOT, E ;
VUILLIER, J ;
MONTCUQUET, P ;
NOIR, A ;
ROZENBAUM, A ;
DESFLORIS, RL .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 69 (03) :345-349